πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to HOOKIPA Pharma Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. logo
Market Cap: Low
Employees: Low

HB-101, HB-201, HB-202, HB-300, HB-700

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing immunotherapeutics for infectious diseases and cancers using a proprietary arenavirus platform. Key products include HB-101 for kidney transplant patients, and HB-201/202 for HPV 16-positive cancers. Preclinical developments target prostate and various cancers.

Tags: arenavirus platform, biopharmaceutical, cancer, clinical trials, collaboration, immunotherapeutics, infectious diseases, oncology, vaccine products

Symbol: HOOK

Recent Price: $2.02

Industry: Biotechnology

CEO: Dr. Malte Peters M.D.

Sector: Healthcare

Employees: 151

Address: 350 Fifth Avenue, New York, NY 10118

Phone: 431 890 6360

Last updated: 2024-12-31

Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALEXIS-ISO-1, ALEXIS-PRO-1

Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.

Tags: T cell therapies, artificial intelligence, biopharmaceutical, cell therapy, oncology

Symbol: KRBP

Recent Price: $0.93

Industry: Biotechnology

CEO: Mr. Pietro Bersani CPA, J.D.

Sector: Healthcare

Employees: 35

Address: 7707 Fannin, Houston, TX 77054

Phone: 832 968 4888

Leadership

  • Pietro Bersani, CPA, Director
  • Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
  • Scott Dahlbeck, MD, PharmD, Chief of Staff
  • Brian Hungerford, Chief Financial Officer
  • Michael Nagel, Chairperson
  • Michael Catlin, Independent Director
  • Pam Misajon, Independent Director

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Immuno Phage platform

Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immunotherapies for cancer, leveraging platforms such as Immuno Phage and Tumor Microenvironment Activated Biologics.

Tags: bacteriophage, biopharmaceutical, cancer treatment, immunotherapy, monoclonal antibodies

Symbol: SNSE

Recent Price: $0.48

Industry: Biotechnology

CEO: Mr. John K. Celebi M.B.A.

Sector: Healthcare

Employees: 28

Address: 451 D Street, Rockville, MD 02210

Phone: 240 243 8000

Last updated: 2024-12-31

Assembly Biosciences, Inc.

Assembly Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Vebicorvir

Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Their lead product candidate, Vebicorvir, has completed Phase 2 clinical trials. The company is engaged in additional development and collaboration agreements to advance treatments for HBV.

Tags: Vebicorvir, biotechnology, clinical trials, hepatitis B, therapeutics

Symbol: ASMB

Recent Price: $16.03

Industry: Biotechnology

CEO: Mr. Jason A. Okazaki

Sector: Healthcare

Employees: 65

Address: 331 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 833 509 4583

Last updated: 2024-12-31

Cue Biopharma, Inc.

Cue Biopharma, Inc. logo
Market Cap: Low
Employees: Lowest

CUE-101

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.

Tags: autoimmune disorders, biopharmaceutical, cancer, chronic diseases, immune system

Symbol: CUE

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Daniel R. Passeri J.D., M.Sc.

Sector: Healthcare

Employees: 53

Address: 21 Erie Street, Cambridge, MA 02139

Phone: 617 949 2680

Leadership

  • Dan Passeri, Chief Executive Officer
  • Anish Suri, President and Chief Scientific Officer
  • Lucinda Warren, Chief Business Officer
  • Matteo Levisetti, Chief Medical Officer
  • Kerri-Ann Millar, Chief Financial Officer
  • Colin Sandercock, Senior Vice President and General Counsel
  • Frank Morich, M.D., Ph.D., Chairman of the Board
  • Dan Passeri, M.Sc., J.D., Chief Executive Officer
  • Peter Kiener, D.Phil.,
  • Fred Driscoll,
  • Patrick Verheyen,
  • Pamela D. Garzone, Ph.D.,

Last updated: 2024-12-31

Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. logo
Market Cap: Lowest
Employees: Not Available

EB103, EB104

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors, with product candidates such as EB103 and EB104. It collaborates with Imugene Limited to develop solid tumor treatments.

Tags: EB103, EB104, Imugene Limited, T-cell therapies, biopharmaceutical, blood cancer, clinical trial, collaboration, solid tumors

Symbol: ESLA

Recent Price: $1.24

Industry: Biotechnology

CEO: Dr. Cheng Liu Ph.D.

Sector: Healthcare

Employees: N/A

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 318 9098

Last updated: 2024-12-31

HilleVax, Inc.

HilleVax, Inc. logo
Market Cap: Low
Employees: Low

HIL-214

Hille Vax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines, including HIL-214, for the prevention of norovirus infection.

Tags: biopharmaceutical, clinical-stage, norovirus, vaccines

Symbol: HLVX

Recent Price: $1.98

Industry: Biotechnology

CEO: Dr. Robert M. Hershberg M.D., Ph.D.

Sector: Healthcare

Employees: 90

Address: 75 State Street, Boston, MA 02109

Phone: 617 213 5054

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • HervΓ© Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

Third Harmonic Bio, Inc.

Third Harmonic Bio, Inc. logo
Market Cap: Medium
Employees: Lowest

THB001

Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing medicine for allergic and inflammatory diseases, including THB001, an oral small-molecule KIT inhibitor for treating chronic urticaria and other indications.

Tags: KIT inhibitor, allergic diseases, biopharmaceutical, chronic urticaria, clinical-stage, inflammatory diseases

Symbol: THRD

Recent Price: $10.38

Industry: Biotechnology

CEO: Ms. Natalie C. Holles

Sector: Healthcare

Employees: 42

Address: 300 Technology Square, Cambridge, MA 02139

Phone: 617-915-6680

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation logo
Market Cap: Medium
Employees: Low

AB-729, AB-836, AB-161, AB-101

Arbutus Biopharma Corporation is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's HBV product pipeline includes RNA interference products and oral capsid inhibitors, and it is involved in strategic alliances for research and development.

Tags: HBV, Hepatitis B, RNA interference, SARS-CoV-2, biopharmaceutical, capsid inhibitor, coronaviruses, therapeutics

Symbol: ABUS

Recent Price: $3.20

Industry: Biotechnology

CEO: Mr. Michael J. McElhaugh

Sector: Healthcare

Employees: 73

Address: 701 Veterans Circle, Warminster, PA 18974

Phone: 267 469 0914

Leadership

  • Michael J. McElhaugh, Interim President and Chief Executive Officer and Director
  • Michael J. Sofia PhD, Chief Scientific Officer
  • Karen Sims, MD, PhD, Chief Medical Officer
  • David C. Hastings, Chief Financial Officer
  • Christopher Naftzger, General Counsel and Chief Compliance Officer
  • Lisa Caperelli, Vice President, Investor Relations
  • Shannon Briscoe, SPHR, SHRM-SCP, Vice President, Human Resources
  • Frank Torti, MD, Chairman
  • Daniel Burgess, Independent Director
  • Richard C. Henriques, Independent Director
  • Keith Manchester, MD, Independent Director
  • James Meyers, Independent Director
  • Melissa V. Rewolinski, PhD, Independent Director

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31